Search clinical trials for: EYLEA

Total 292 results

Bayer
Regeneron Pharmaceuticals

Not yet recruiting

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (PHOTONiC)

Diabetic Macular Edema
Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy
Bayer

Recruiting

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Preterm Infants | Retinopathy of Prematurity

United Kingdom
Sohag University

Recruiting

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Diabetic Macular Edema

Egypt
Caregen Co. Ltd.
CBCC Global Research

Not yet recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals; Genzyme, a Sanofi Company

Recruiting

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
4D Molecular Therapeutics

Recruiting

4D-150 in Patients With Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
RemeGen Co., Ltd.

Recruiting

Efficacy and Safety of RC28-E Versus Aflibercept

Wet Age-related Macular Degeneration

China
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Shin Kong Wu Ho-Su Memorial Hospital

Recruiting

Maximum Treatment Interval With Aflibercept T&E

Neovascular Age-related Macular Degeneration

Taiwan
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Macular Edema

United Arab Emirates
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Macula Lutea Degeneration

United Arab Emirates
Uptown Eye Specialists

Not yet recruiting

Ozurdex in Suboptimal Diabetic Macular Edema Patients (DME)

Diabetic Macular Edema
Chiang Mai University

Recruiting

Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Polypoidal Choroidal Vasculopathy

Thailand
King's College Hospital NHS Trust
King's College London; Fight for Sight (Funder)

Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). (TIGER)

Eye Diseases | Macular Degeneration, Wet | Sub-Macular Hemorrhage

United Kingdom
Kim's Eye Hospital
Bayer

Recruiting

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Retinal Angiomatous Proliferation

Korea, Republic of
M. Ali Khan, MD
University of California, Los Angeles; Southeastern Retina Associates; Eye Associates...

Recruiting

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair (PREVENT-PVR)

Proliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified Eye

United States
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

Not yet recruiting

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Age Related Macular Degeneration
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Vastra Gotaland Region

Recruiting

The Sahlgrenska Anti-VEGF Study (SAHLVE)

Neovascular Age-related Macular Degeneration

Sweden
Centre Hospitalier Universitaire Dijon

Recruiting

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (TELeMAC)

Macular Telangiectasia

France
Bay Area Retina Associates
Allergan

Recruiting

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (STAMP)

Diabetic Macular Edema | Cataract

United States
Unity Health Toronto

Recruiting

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept (COVARIANT)

Diabetic Macular Edema | Macular Edema | Retinal Vein Occlusion | Age Related Macular Degeneration

Canada
Kagawa University

Recruiting

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Macular Disease

Japan
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
University of Athens

Completed

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (INTRAMED-CRVO)

Retinal Vein Occlusion | Vascular Occlusive Disease
Regeneron Pharmaceuticals

Active, not recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
The University of Hong Kong

Completed

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Age-Related Macular Degeneration

Hong Kong
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)

Retinopathy of Prematurity (ROP)

Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Czechia, Greece, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Hungary, Belgium and more
Moorfields Eye Hospital NHS Foundation Trust
Bayer

Completed

Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study (AMOUR)

Retinitis Pigmentosa | Macular Oedema

United Kingdom
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)

Wet Age-related Macular Degeneration

United States, Puerto Rico
Bayer

Completed

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (VISION-AF)

Diabetic Macular Edema

India
Wake Forest University Health Sciences

Terminated

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Retinal Vein Occlusion

United States
Jaeb Center for Health Research

Completed

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (DRCR AC)

Diabetic Macular Edema

United States
Singapore National Eye Centre
National University Hospital, Singapore; Tan Tock Seng Hospital

Active, not recruiting

Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

Polypoidal Choroidal Vasculopathy

Singapore
Texas Retina Associates
The Emmes Company, LLC

Completed

One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)

Diabetic Macular Edema

United States
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Seoul National University Hospital

Completed

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Age-Related Macular Degeneration

Korea, Republic of
McMaster University

Active, not recruiting

Mean Visual Acuity Changes Following Five Injections of Aflibercept

Diabetic Macular Edema

Canada
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
National Cancer Institute (NCI)

Completed

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Ovarian Carcinoma | Pancreatic Neuroendocrine Tumor | Unresectable Solid Neoplasm | Fibrolamellar Carcinoma

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States

Search clinical trials for: EYLEA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations